Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country

• Main Authors: Edward Mezones-Holguin (Author), Rocio Violeta Gamboa-Cardenas (Author), Gadwyn Sanchez-Felix (Author), José Chávez-Corrales (Author), Luis Miguel Helguero-Santin (Author), Luis Max Laban Seminario (Author), Paula Alejandra Burela-Prado (Author), Maribel Marilu Castro-Reyes (Author), Fabian Fiestas (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Biological products, including infliximab (INF), are a therapeutic option for various medical conditions. In the Peruvian Social Security (EsSalud), infliximab is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthropathy, ankylosing spondylitis, ulcerative co...